Venter and his partner in technology, Tony White, need to sell a lot more of it if they are to have any hope of translating that gene sequence into useful medical products.
Lately, Applied has taken over Celera's original business, selling gene-sequence subscriptions to drug companies, while Celera focuses on developing its own products.